VolitionRx Consensus Price Target Decreased by 17.44% to $13.89
The average one-year price target for VolitionRx (NYSEAM:VNRX) has been revised to $13.89 / share. This is a decrease of 17.44% from the prior estimate of $16.83 dated September 11, 2026. These figures represent aggregate analyst targets compiled by Fintel and do not constitute a recommendation orinvestment adviceby Fintel.
The price target is an average of many targets provided by analysts. The latest targets range from a low of $2.02 to a high of $25.20 / share. The average price target represents an increase of 5,820.09% from the latest reported closing price of $0.23 / share.
This revision marks a continuation of a downward trend in analyst expectations. The mean target has decreased for 3 consecutive periods, moving from $17.31 on August 4, 2026, to $16.90 on August 28, 2026, then to $16.83 on September 15, 2026, and finally to $13.89 as of October 2, 2026. This represents a target change of -19.71% since the 90-day baseline date of June 30, 2026. Over a longer horizon, the observed twelve-month high mean target was $29.79 on May 14, 2026, while the observed twelve-month low mean target was $1.73 on April 28, 2026. The current median target remains unchanged at $20.40, resulting in a mean-median gap of $6.51.
As context for the company's market environment, VolitionRx's stock price has experienced recent declines. The stock's closing price of $0.23 on October 1, 2026, reflects a one-week price change of -4.52% from a baseline close of $0.25 on September 24, 2026, and a one-month price change of -40.46% from a baseline close of $0.39 on September 1, 2026. In its latest earnings report on August 13, 2026, VolitionRx reported an actual EPS of -0.85, compared to an estimated EPS of -0.5855. Actual revenue was $398,000.00, which fell short of the estimated $492,323.00, representing a revenue surprise of -19.16%.
Analyst sentiment remains positive overall. As of September 1, 2026, the recommendation breakdown represents 81.8% positive recommendations and 18.2% hold recommendations, which is unchanged from the August 1, 2026 period. Within the Construction & Engineering sub-industry, which covers 29 companies, 7 companies saw target increases, 13 saw decreases, and 9 remained unchanged. The sub-industry median revision percent was 0.00%, with a median implied change percent of +71.39%.
In comparison to peers in the diagnostics and oncology space, VolitionRx's target revision contrasts with the upward or flat revisions seen among its peers. Guardant Health and Natera both experienced positive target revisions, while NeoGenomics remained unchanged.
| Company Name | Target revision | Implied change |
|---|---|---|
| Guardant Health | +1.33% | +12.38% |
| Natera | +3.01% | -15.14% |
| NeoGenomics | 0.00% | +13.14% |
Fintel is one of the most comprehensive investing research platforms available to individual investors, traders, financial advisors, and small hedge funds.
Our data covers the world, and includes fundamentals, analyst reports, ownership data and fund sentiment, options sentiment, insider trading, options flow, unusual options trades, and much more. Additionally, our exclusive stock picks are powered by advanced, backtested quantitative models for improved profits.
This story originally appeared on Fintel.